Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

First-in-human trial is now open for enrollment for EBT-101, a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIV